Exercise-induced asthma Respiratory
Conditions
Interventions
Participants were randomised to a 21-day supplementation of a daily dose of 8 capsules (4 to be taken am, 4 to be taken pm) of either:
1. 6.2 g/day Omega 3 polyunsaturated fatty acid dose (3.7 g EPA a
Sponsors
Nottingham Trent University (UK)
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1. Body mass index (BMI) 20-25 kg.m-2 2. Physically active 3 or more times a week , with each exercise session lasting at least 45 min 3. Non-smoker 4. Non-vegetarian or vegan 5. Asthma sufferers must have own clinically prescribed medication 6. Asthma sufferers must have a GP diagnosis
Exclusion criteria
Exclusion criteria: 1. Predicted forced expiratory volume in 1 second (FEV1) less than 65% 2. Previously diagnosed with COPD, emphysema, chronic bronchitis or similar respiratory illness 3. Previously admitted to hospital for asthma or other breathing difficulties 4. Asthma exacerbation within the last month (course of steroids or hospital visit) 5. History of heart failure, pulmonary hypertension, embolism, or other pulmonary heart disease 6. History of recurrent chest infections 7. Smoker 8. Acute infection within the last four weeks 9. Major operation within the past four months 10. Have a history of taking ?-3 PUFA supplements or supplements with antioxidants above recommended intake, or consume more than three fatty fish meals per week 11. Take a daily dose of aspirin or other NSAIDs 12. Currently taking a daily dose of anti-histamine 13. Currently taking long-term asthma maintenance medications – corticosteroids, and leukotriene modifiers that you could not refrain from taking for 4 days prior to laboratory session
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pulmonary function data (forced expiratory volume in 1 second, forced vital capacity, and peak expiratory flow) at baseline and in response to the eucapnic voluntary hyperpnoea test (in both asthmatic and non-asthmatic groups). Data was collected at day 0 and day 21 of each intervention | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Fraction of exhaled nitric oxide 2. Urinary concentration of 9alpha, 11beta-PGF2 at baseline and in response to the eucapnic voluntary hyperpnoea test 3. Neutrophil phospholipid fatty acid analysis as a measure of intervention compliance Data was collected at day 0 and day 21 of each intervention | — |
Countries
United Kingdom
Outcome results
None listed